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INTRODUCTION
Aspergillus species cause life-threatening fungal pneumonia, guttural pouch infections, and fungal keratitis in horses (Gerard et al., 2006) . The most ubiquitous and pathogenic Aspergillus species documented in equine veterinary literature are Aspergillus fumigatus, Aspergillus flavus, Aspergillus nidulans, and Aspergillus niger (Cafarchia et al., 2012) . Fungal infections in horses are clinically challenging with regard to limited therapeutic treatments and overwhelming expense for the client. The polyene antibiotics and the azoles are the two common classes of antifungal drugs used in equine medicine. Unfortunately, options for the oral treatment of fungal infections are limited by bioavailability and cost. The pharmacokinetics of ketoconazole, itraconazole, fluconazole, and voriconazole in horses have been studied (Prades et al., 1989; Latimer et al., 2001; Davis et al., 2005 Davis et al., , 2006 . Itraconazole and voriconazole have activity against Aspergillus and are absorbed following oral administration (Davis et al., 2005 (Davis et al., , 2006 , but the cost prohibitive nature of most oral antifungal treatments in equine patients limits owner compliance, thus worsening the prognosis for fungal diseases in horses.
Terbinafine (Lamisil â ) is an allylamine antifungal drug approved for use in humans. This allylamine is both fungicidal and fungistatic. Terbinafine prevents the biosynthesis of ergosterol (necessary for cell membrane synthesis) by the inhibition of squalene epoxidase. The intracellular accumulation of squalene is cytotoxic (Ryder & Favre, 1997) . The depletion of ergosterol interferes with cell membrane function and growth. Terbinafine has antifungal activity alone or in multidrug combinations against fungal organisms including Candida albicans, Malassezia pachydermatis, Blastomyces dermatitidis, Cryptococcus neoformans, Histoplasma capsulatum, Microsporum canis, and Aspergillus species (Shadomy et al., 1985; Goudard et al., 1986; Petranyi et al., 1987; Saarikoski et al., 2015) . Terbinafine is well absorbed after oral administration in small animal species and humans, but oral bioavailability in horses is incomplete due to first pass metabolism (Williams et al., 2010) . Drug clearance is primarily through hepatic biotransformation into numerous inactive metabolites. Williams and colleagues found that the terminal half-life after oral administration of terbinafine was 8.1 h, but the mean maximum plasma concentration (C MAX ) was only 0.31 lg/mL after a single 20-mg/kg p.o. dose. The drug was well tolerated, but did not achieve adequate plasma concentrations to exceed the entire MIC range (0.05-2 lg/mL) for relevant Aspergillus spp. (Shadomy et al., 1985; Goudard et al., 1986; Petranyi et al., 1987) .
Drug-drug interactions with terbinafine have been published (Saarikoski et al., 2015) . For instance, CYP450 is a hepatic enzyme system that metabolizes terbinafine; alterations in this enzyme system have direct effects on subsequent plasma drug concentrations. Cimetidine is a CYP450 inhibitor that is occasionally administered in combination with terbinafine in humans. This drug interaction results in an increased plasma concentration of terbinafine and a 33% decrease in terbinafine clearance in humans (Anonymous, 2015) .
The veterinary literature on terbinafine administered alone or in antifungal drug combinations has been shown to be clinically effective and well tolerated in domesticated and nondomesticated animals. However, pharmacokinetic and efficacy studies of oral terbinafine in horses are limited. Williams et al. (2010) 
MATERIALS AND METHODS

Animals
The Institutional Animal Care and Use Committee at Kansas State University approved the study. This crossover systematically randomized study used six adult healthy horses, ranging in age and weight from 8 to 17 years and 490 to 620 kg, respectively. The breeds included three Quarter Horses, one Paint, one Trakehner, and one Thoroughbred. Three of the horses were mares, and three were geldings. The horses were acclimated to the indoor stalls the day prior to drug administration. Horses were offered brome or prairie hay and water ad libitum throughout the study, consistent with their routine roughage diet. Horses were fed their routine ration between 2 and 3 pounds of pelleted feed, twice daily. Prior to study enrollment, a physical examination and complete blood count were conducted and were found to be within species-and age-specific reference intervals. Animals were monitored for 24 h after drug administration.
Drug dosing treatments
The study consisted of four treatments using terbinafine tablets (terbinafine hydrochloride, 250 mg tablets; Liconsa, Guadalajara, Spain). Terbinafine was administered p.o. (30 mg/kg) to all six horses; terbinafine was administered p.o. (30 mg/kg) to all six horses 2 h after 30 mg/kg p.o. cimetidine (cimetidine, 400 mg tablet; Novopharm Limited, Toronto, ON, Canada); three randomly chosen horses received terbinafine tablets (30 mg/kg) crushed and suspended in water per rectum, and three horses received terbinafine tablets (30 mg/kg) crushed and suspended in olive oil per rectum. For the oral administration, both terbinafine and cimetidine tablets were crushed individually with a mortar and pestle and were combined with water and molasses to make a paste-like consistency. Two 35-cc dosing syringes were used to administer total drug volume. The tablet total administered to each horse was rounded to the nearest whole tablet, regardless of route. At least 7 days was allowed between each treatment as a washout period.
Blood sampling for plasma analysis of terbinafine
Intravenous jugular catheters were aseptically placed for blood collection. Whole blood (9 mL) was collected and discarded prior to sample collection to ensure that samples were not contaminated with heparinized saline. Whole blood (9 mL) was collected at each time point followed by the catheter being flushed with 12 mL of heparinized (4 IU/mL) saline. The whole blood was transferred into tubes containing lithium heparin at times 0 (prior to drug administration), 10 min, 20 min, 30 min, 45 min, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after drug administration. Blood was kept on ice until separation by centrifugation. Blood was centrifuged for 15 min at 30009 g; plasma was separated and stored frozen at À70°C until analysis with LC/MS/MS. concentration. Plasma standards, quality control samples, and plasma samples were extracted identically using pass-through sample preparation to remove phospholipids and proteins (Ostro Pass-through Sample plates, Waters). Plasma, 50 lL, was added to the plates, followed by 150 lL acetonitrile with 1% formic acid and 500 ng/mL tolnaftate, which was mixed and then the precipitate passed through the sample plates. The injection volume was 0.5 lL. A C18 column (CSH C18+, 50 9 2.1 mm, 1.7 lm pore size, Waters, Milford, MA, USA) maintained at 55°C was used for separation. The mobile phase consisted of A: 0.2% formic acid in deionized water and B: acetonitrile at a flow rate of 0.8 mL/min. The mobile phase gradient started at 70% A with a linear gradient to 100% B at 0.3 min, which was held until 0.89 min with a step to 70% A at 0.9 min with a total run time of 1.5 min. The accuracy of the assay was determined on replicates of five quality control samples in pooled untreated equine plasma fortified with 0.005, 0.05, and 1 lg/mL terbinafine and were within 1, 1, and 4% of expected concentrations, respectively. The coefficient of variation was determined on replicates of five quality control samples at 0.005, 0.05, and 1 lg/mL and were 6, 8, and 4%, respectively.
Plasma concentrations of terbinafine
Pharmacokinetics and statistical analysis
Noncompartmental pharmacokinetic analysis was completed using computer software (Phoenix 64, Certara, Princeton, NJ, USA). The pharmacokinetic values for each individual were calculated, and the geometric mean and range (minimummaximum) are reported (Julious & Debarnot, 2000) . The following pharmacokinetic parameters were calculated: AUC 0-INF = area under the curve extrapolated to infinity using the linear trapezoidal method; AUC Extrap = percent of the AUC extrapolated to infinity; AUC 0-LAST = area under the curve from time 0 to the last concentration above the lower analytical limit of quantification; Cl/F = clearance per fraction of the dose absorbed; T½ = terminal half-life; kz = terminal rate constant; MRT = mean residence time extrapolated to infinity; Vz/F = volume of distribution (area method) per fraction of the dose absorbed. The C MAX = maximum plasma concentrations and T MAX = time of C MAX were determined directly from the data. The relative F = fraction of the dose of terbinafine with cimetidine absorbed relative to oral terbinafine alone was calculated with the following equation:
Terbinafine AUC 0ÀINF with cimetidine Terbinafine AUC 0ÀINF administered alone Statistical analysis of the pharmacokinetic data was performed with computer software (Sigma Plot 12.5, Systat, Chicago IL, USA) using Mann-Whitney rank-sum analysis (Powers, 1990) . The significance was set at P < 0.05. The pharmacokinetic parameters of p.o. terbinafine administered alone were compared to the pharmacokinetic data of p.o. terbinafine administered concurrently with p.o. cimetidine. One horse each in the terbinafine (horse #1, 61%) and terbinafine with cimetidine (horse #2, 47%) had excessive extrapolation of the AUC, which could lead to inaccurate estimates of some pharmacokinetic parameters. Therefore, the only PK parameters reported and statistically assessed from those horses were the AUC 0-LAST , C MAX, and T MAX . The relative fraction of the dose absorbed was calculated in four horses as horse #1 (terbinafine) and horse #2 (terbinafine with cimetidine) had excessive extrapolation of the AUC 0-INF . Per rectum pharmacokinetic analysis was not conducted for either suspension due to the low number of plasma concentrations exceeding the lower limit of analytical quantification.
RESULTS
The plasma concentrations of p.o. terbinafine alone and in combination with cimetidine are illustrated in Fig. 1 . The mean maximum plasma concentrations of p.o. terbinafine administered alone and terbinafine with cimetidine were 0.291 lg/mL at 1.54 h and 0.417 lg/mL at 1.28 h, respectively (Table 1) . Terbinafine with cimetidine achieved an average 44% higher C MAX and 30% higher AUC 0-LAST compared to oral terbinafine alone. The mean relative F of terbinafine with cimetidine was 153% using AUC 0-INF . However, these parameters were not statistically different (P > 0.05). No statistical difference in any pharmacokinetic parameter was found between the two treatment protocols. The highest measured concentration of terbinafine after per rectum administration of terbinafine suspended in water to three horses was 0.059 lg/mL. The highest measured concentration of terbinafine after per rectum administration of terbinafine suspended in olive oil to three horses was 0.013 lg/mL. Most of the plasma concentrations after per rectum administration of terbinafine were below the analytical lower limit of quantification (0.005 lg/mL) precluding pharmacokinetic analysis. Adverse effects were observed in three horses and were considered minor including nostril flaring and excessive tongue movements. One horse in the terbinafine with cimetidine group developed a fever (102.2 F) 12 h post-terbinafine administration. Another horse during catheter placement started showing signs of colic, which was unrelated to drug administration. All reported adverse effects resolved spontaneously without medical intervention.
DISCUSSION
To the authors' knowledge, this is the first terbinafine pharmacokinetic study assessing a 30-mg/kg p.o. dose, the first study assessing the effects of cimetidine on terbinafine and the first study assessing the pharmacokinetics of per rectum terbinafine in horses. In vitro studies suggest terbinafine may have clinical efficacy for many fungal species including Aspergillus spp., Fusarium spp., Paecilomyces spp., C. albicans, dematiaceous molds, and Scedosporium prolificans, but clinical efficacy studies have not been reported for most of the organisms (Shadomy et al., 1985; Goudard et al., 1986; Petranyi et al., 1987) . The reported MICs for Aspergillus species are as follows: A. fumigatus MIC range -0.2-5 lg/mL, A. flavus MIC range 0.02-0.05 lg/ mL, and A. niger MIC range 0.02-0.2 lg/mL. Aspergillus spp are commonly treated with systemic itraconazole, voriconazole, and amphotericin B, but the in vitro activity of terbinafine suggests it could be a reasonable systemic treatment choice for some Aspergillus isolates.
The plasma concentrations of p.o. terbinafine after a 30 mg/ kg and 30 mg/kg p.o. in combination with p.o. cimetidine exceeded the reported upper MIC range of A. flavus from 20 min to 8 h, but the mean concentrations were below the upper MIC range at 12 and 24 h. Plasma concentrations exceeding the MIC ranges for A. niger were achieved in some, but not all horses. None of the horses achieved plasma concentrations exceeding the upper MIC range of A. fumigatus. It is important to note that these MICs were not for equine isolates, so it is unclear whether the MICs for equine isolates are within similar ranges. Multiple-dose administration could result in drug accumulation achieving higher plasma concentrations, and administering terbinafine every 12 or 8 h is expected to result in higher drug concentrations. Further studies are needed to determine the multiple-dose pharmacokinetics, adverse effects, and the optimum dosing intervals of p.o. terbinafine in horses.
A study by Ryder and Leitner (2001) observed a synergistic pharmacodynamic interaction of terbinafine when combined with other antifungal agents against A. fumigatus and A. flavus isolates. That investigation concluded the combination of terbinafine with fluconazole achieved additive to synergistic effects decreasing the terbinafine MIC by one to two dilutions compared to terbinafine alone. Therefore, the therapeutic efficacy of terbinafine may be enhanced by pharmacokinetic interactions (i.e., inhibition of metabolism) and by pharmacodynamic interactions (i.e., addition of fluconazole) in the horse. However, further studies are needed to assess the efficacy and safety of antifungal drug combinations and use of metabolism inhibitors in horses.
Although in the current study the combination of terbinafine with cimetidine resulted in a higher plasma concentration (C MAX and AUC's) than terbinafine administered alone, this difference was not statistically significant. The increase in plasma concentrations may be due to the inhibitory effects of cimetidine on the hepatic or intestinal metabolizing enzyme systems. An interaction is documented in humans administered terbinafine with cimetidine resulting in a 33% decrease in the oral clearance which is also expected to increase the AUC Extrap , percent of the AUC extrapolated to infinity; AUC 0-LAST , area under the curve from time 0 to the last concentration above the lower analytical limit of quantification; AUC 0-INF , AUC extrapolated to infinity; Cl/F, clearance per fraction of the dose absorbed; C MAX , maximum plasma concentrations; T½, terminal half-life; kz, terminal rate constant; MRT, mean residence time extrapolated to infinity; T MAX , time of C MAX ; Vz/F, volume of distribution (area method) per fraction of the dose absorbed; relative % F, fraction of the dose absorbed relative to oral terbinafine administered alone. The P-value comparing oral terbinafine alone to oral terbinafine combined with oral cimetidine was calculated using the Mann-Whitney rank-sum test.
AUC (Anonymous, 2015) . The FDA defines a weak inhibitor as an inhibitor resulting in a 25-100% increase in the AUC of the substrate. Based on the results of this study, cimetidine can be considered a weak inhibitor of terbinafine metabolism in the horse. If moderate (100-500% increase in terbinafine AUC) or strong inhibitors (>500% increase in terbinafine AUC) of terbinafine metabolism in horses are found, then the potential clinical utility of terbinafine would be markedly increased.
Per rectum drug administration resulted in low plasma concentrations when compared to the oral route. The rationale of using the per rectum route in horses is aimed at reducing adverse effects observed with oral administration while in addition, potentially improving systemic drug exposure due to reduced first pass metabolism. Low rectal bioavailability may have been due to poor water solubility of terbinafine, presystemic metabolism, or interactions with rectal contents. A pilot study using three horses each assessed terbinafine suspended in water or olive oil at doses of 30 mg/kg terbinafine. Data from the pilot study using terbinafine suspended with olive oil revealed poor rectal absorption, similar to the water suspension. Based on these data, terbinafine administered p.o. produced superior systemic drug exposure compared to per rectum.
Adverse effects demonstrated by the horses in this study included asymptomatic fever and oral irritation. This mild elevation in temperature may have been due to environmental conditions in the barn, excitement/stress from the study, or systemic drug adverse effect (van Puijenbroek et al., 2001) . Oral adverse effects observed in this report correlated with the previous study by Williams et al., 2010 . In our study, the primary investigator found mixing crushed terbinafine tablets with water and molasses (p.o.) made a paste-like consistency. This formulation may have caused the minor oral adverse effects observed in three horses.
Limitations of this study include only a single terbinafine dose was administered, so no conclusions can be made on multiple dosing protocols in horses at this time. A healthy population of adult horses was used in this investigation, so conclusions of drug plasma concentrations in sick adult horses or foals cannot be determined. The horses hepatic and renal values were not evaluated after the terbinafine administration, so no conclusions could be made on systemic adverse effects; however, clinical examination of all horses was normal throughout the study duration. Relative bioavailability was calculated due to the lack IV drug formulation to obtain the true percent bioavailability. The number of horses investigated in this study is a limitation when determining a statistical difference among the drug protocols in question due to the observed variability.
CONCLUSIONS
Orally dosed terbinafine with cimetidine did not produce severe adverse effects when a single dose was administered to adult horses. Orally dosed terbinafine compared to per rectum is superior with regard to drug plasma concentration. Potential oral irritation, palatability, or fever should be considered adverse effects when administering terbinafine to horses. More pharmacokinetic studies are indicated to determine the safest, highest, and most cost-effective terbinafine dose administered orally alone and/or in combination with cimetidine in adult horses. Pharmacokinetic studies using multiple dosing intervals will improve our knowledge of a potential residual drug accumulation and potential systemic side effects in horses. Further randomized case-control studies are indicated to assess the clinical efficacy of terbinafine for the treatment of fungal diseases in adult horses.
